Smoking in United States of America
In the United States of America, smoking is allowed but tobacco products should follow some regulations. Under these regulations, health warnings on tobacco packaging including cigarettes are mandatory, the minimum legal age for their sales is 21 years, and there are no federal legal restrictions on smoking in public places. While tobacco advertising is regulated, not all forms of their advertising are banned. An excise tax of 32.16% with a total taxation rate of 37.36% is applied on cigarettes. Cigarettes can legally be sold with authorised documents. They may also be purchased through vending machines as well as through online channels. Importing cigarettes for trade is allowed with an appropriate import license. Despite these control measures, prevalence data show that smoking remains an important public health issue in the United States. There were 39.8 million current smokers in the country in 2024. This represents an overall adult smoking prevalence of 14.1%, with higher prevalence among men (17.1%) than among women (11.1%). In comparison, the overall current smoking prevalence was 12.3% in 2022. The adult daily smoking prevalence was recorded to be 10.01% in 2020. Smoking-related mortality also remains significant in the country. In 2021, smoking resulted in 360,370 deaths, including 216,986 male deaths and 143,383 female deaths. This shows that smoking accounted for 10.38% of all deaths in the United States in 2021, with a higher rate among men (11.9%) than among women (8.7%).
Read articles from United States of America
September 29, 2026 by drvinayprasad.com
Public health fails in ways it can’t even see
Public health can fail quietly when it counts intentions more carefully than consequences. Campaigns, restrictions and official messages may be designed to protect people, yet still produce confusion, mistrust or worse choices in the real world. Nicotine policy is a clear example: caution becomes harmful when it hides the difference between smoking and lower-risk alternatives. A stronger public health culture would measure what its advice actually does, not only what it was meant to do.
September 28, 2026 by clearingtheair.eu
Major review finds nicotine pouches considerably less toxic than cigarettes
Toxicity is where the nicotine debate needs less rhetoric and more comparison. A major review finding nicotine pouches considerably less toxic than cigarettes reinforces the basic harm reduction point: the way nicotine is delivered changes the risk profile. Smoke-free does not mean risk-free, but it does mean the absence of combustion and far lower exposure to many harmful toxicants. Policy should reflect that difference instead of treating pouches and cigarettes as interchangeable threats.
September 28, 2026 by tobaccoharmreduction.net
Nicotine Risk Insurance Pricing: What Reinsurers Say
Insurance pricing can reveal how poorly nicotine risk is understood. Treating every nicotine user like a smoker ignores the difference between combustible tobacco and smoke-free alternatives such as pouches, snus or vaping. That matters because premiums can punish people who have reduced their risk by leaving cigarettes behind. A fairer approach would price risk according to evidence, exposure and product type — not according to nicotine use alone.
September 28, 2026 by regulatorwatch.com
Decisive Move | Haypp Goes All-In on U.S. Nicotine Pouch Market | RegWatch
Haypp’s move into the US nicotine pouch market reflects more than business expansion. It signals growing consumer demand for smoke-free products that are convenient, discreet and separate from combustion. That shift matters because markets can either be shaped through responsible standards or left to develop without enough oversight. A strong harm reduction framework should make room for adult access, product accountability and clear information about where pouches sit on the risk spectrum.
September 25, 2026 by wsj.com
U.S. Regulators Plan Major Move to Speed Authorizations of Vapes, Tobacco Pouches
A faster FDA pathway for vapes and nicotine pouches would matter most for the legal market. Years of slow authorisations have left adult smokers with limited approved options while illicit and unapproved products fill the gap. Speed should not mean weak standards; it should mean timely, evidence-based decisions that distinguish responsible smoke-free products from those that fail basic tests. Harm reduction needs regulation that can move quickly enough to keep safer alternatives inside accountable channels.
September 24, 2026 by substack.com
Teen Vaping Is Falling in Pennsylvania...so why does the state still say it is skyrocketing
Pennsylvania’s teen vaping trend tells a less dramatic story than many policy campaigns suggest. Youth use is falling, yet the political response often remains locked in crisis mode, with restrictions aimed at a problem that may already be moving in the right direction. That matters because outdated alarm can distort priorities and spill over onto adults who smoke. Prevention should follow the data, not preserve a panic after the trend has changed.
September 24, 2026 by substack.com
Knowledge is Power
Knowledge is power in tobacco harm reduction because it gives smokers something more useful than fear. Understanding combustion, nicotine, relative risk and switching can change the choices people believe are available to them. Poor information keeps cigarettes protected by confusion, while clear information helps adults see a route away from the most harmful product. Public health should not be afraid of informed consumers; it should depend on them.
September 23, 2026 by substack.com
Knowledge is Power
Knowledge is power in tobacco harm reduction because it gives smokers something more useful than fear. Understanding combustion, nicotine, relative risk and switching can change the choices people believe are available to them. Poor information keeps cigarettes protected by confusion, while clear information helps adults see a route away from the most harmful product. Public health should not be afraid of informed consumers; it should depend on them.
September 23, 2026 by 2firsts.com
Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
A nicotine substitute entering the market before key human evidence is available should make regulators ask better questions, not reach for easy assumptions. New molecules such as 6-methyl nicotine may sit outside familiar tobacco and nicotine frameworks, but that does not make them automatically safer, riskier or irrelevant. The priority should be transparent testing, pharmacology, exposure data and real-world monitoring before public health claims are made. Innovation can support harm reduction only when the evidence keeps pace with the product.
September 23, 2026 by 2firsts.com
Can Nicotine Be Replaced? 6-MN Is Already on the Market While Key Human Evidence Is Still Missing
A nicotine substitute entering the market before key human evidence is available should make regulators ask better questions, not reach for easy assumptions. New molecules such as 6-methyl nicotine may sit outside familiar tobacco and nicotine frameworks, but that does not make them automatically safer, riskier or irrelevant. The priority should be transparent testing, pharmacology, exposure data and real-world monitoring before public health claims are made. Innovation can support harm reduction only when the evidence keeps pace with the product.